Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

Doctors caution that while Ozempic can help manage diabetes and obesity under medical supervision, misuse as a weight-loss ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

The European Medicines Agency (EMA) has recommended extending the use of Mounjaro to younger patients with diabetes, ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Ozempic has officially arrived in India at a comparatively affordable price, sparking buzz among diabetes and weight loss ...